​

Artiva Biotherapeutics (ARTV) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ARTV Stock Forecast

Artiva Biotherapeutics (ARTV) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $37.50, with a high of $40.00 and a low of $35.00. This represents a 291.44% increase from the last price of $9.58.

ARTV Stock Rating

Artiva Biotherapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

ARTV Price Target Upside V Benchmarks

TypeNameUpside
StockArtiva Biotherapeutics291.44%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-22
Avg Price Target-$37.50$37.50
Last Closing Price$9.58$9.58$9.58
Upside/Downside-291.44%291.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2615---6
May, 2615---6
Apr, 2615---6
Mar, 2615---6
Feb, 2615---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 11, 2026David NierengartenWedbush$40.00$11.15258.74%317.54%
May 08, 2026H.C. Wainwright$35.00$11.84195.61%265.34%
Aug 13, 2024David NierengartenWedbush$18.00$11.2260.43%87.89%
Aug 13, 2024Gil BlumNeedham$23.00$11.22104.99%140.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 26, 2026Cantor FitzgeraldOverweightOverweighthold
May 12, 2026NeedhamBuyBuyhold
May 11, 2026WedbushOutperformOutperformhold
May 08, 2026H.C. WainwrightBuyBuyhold
Oct 17, 2025WedbushOutperformOutperformhold
Dec 30, 2024H.C. WainwrightBuyinitialise
Sep 03, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024NeedhamBuyinitialise
Aug 13, 2024WedbushOutperforminitialise
Aug 13, 2024Cowen & Co.Buyinitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 24 Dec 25
Dec 24Dec 25
Reported$-5.20$-3.43
Avg Forecast$-4.95$-2.83
High Forecast$-3.63$-2.42
Low Forecast$-6.25$-3.21
Surprise %5.05%21.20%

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 24 Dec 25
Dec 24Dec 25
Reported$251.00K-
Avg Forecast$400.00K$75.36M
High Forecast$550.00K$75.36M
Low Forecast$250.00K$75.36M
Surprise %-37.25%-

Net Income Forecast

$-85M $-72M $-59M $-46M $-33M $-20M Dec 24 Dec 25
Dec 24Dec 25
Reported$-58.49M$-83.86M
Avg Forecast$-46.31M$-26.47M
High Forecast$-33.96M$-22.64M
Low Forecast$-58.47M$-30.03M
Surprise %26.32%216.79%

ARTV Forecast FAQ

Is Artiva Biotherapeutics stock a buy?

Artiva Biotherapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Artiva Biotherapeutics is a favorable investment for most analysts.

What is Artiva Biotherapeutics's price target?

Artiva Biotherapeutics's price target, set by 4 Wall Street analysts, averages $37.5 over the next 12 months. The price target range spans from $35 at the low end to $40 at the high end, suggesting a potential 291.44% change from the previous closing price of $9.58.

How does Artiva Biotherapeutics stock forecast compare to its benchmarks?

Artiva Biotherapeutics's stock forecast shows a 291.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Artiva Biotherapeutics over the past three months?

  • June 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.